An asset manager reports owning 1.48 million shares of CONMED (CNMD).
Fuller & Thaler Asset Management, Inc. has filed an amended beneficial-ownership report (SCHEDULE 13G/A) for CONMED Corp (CNMD), disclosing a 4.94% stake. The asset manager beneficially owns 1,480,161 common shares of CONMED, with the event date for this filing being September 30, 2026. Fuller & Thaler also reported sole voting power over 1,477,298 shares and sole dispositive power over 1,480,161 shares.
CONMED at Jefferies Global Healthcare Conference: growth drivers build By Investing.com
CONMED Corporation outlined its business strategy at the Jefferies Global Healthcare Conference, emphasizing steady growth driven by stable demand in core markets, strong adoption of key products like AirSeal and Buffalo Filter, and new legislative support for smoke evacuation. The company expects mid-single-digit revenue growth and approximately 10% EPS growth, but anticipates cost pressures from raw materials and freight in 2027. Management also discussed the transition period for BioBrace in the U.S. and its M&A strategy, aiming for further deleveraging while considering acquisitions in general surgery and orthopedics.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED Corporation (CNMD) is recommended for retention in portfolios due to strong growth drivers such as the adoption of AirSeal, Buffalo Filter, and BioBrace platforms. The company benefits from rising robotic procedure volumes and expanding Ambulatory Surgery Centers, with its stock outperforming the industry and S&P 500. However, challenges include U.S. Orthopedic weakness, volatility in OEM Buffalo Filter sales, and less predictable international growth due to distributor order timing.
Is Lowered Sales Guidance Altering The Investment Case For CONMED (CNMD)?
CONMED reported Q3 2026 sales of US$335.56 million and net income of US$19.8 million, with EPS of US$0.66. The company adjusted its full-year 2026 net sales guidance slightly lower to a US$1.36b to US$1.366b range, emphasizing margin execution and product mix over rapid top-line expansion. The investment narrative for CONMED continues to focus on profitability driven by higher-margin platforms despite modest revenue growth, with analysts projecting US$1.6b revenue and US$179.7 million earnings by 2029.
CONMED (CNMD) Stock Looks Like A Bargain Despite Its 65% Fall
CONMED (CNMD) shares have fallen 64.7% over the past five years, but the current rebound and a P/E ratio of 20.9x suggest it may be undervalued compared to the broader medical equipment industry average of 25.7x. While the market might be applying a discount due to concerns about execution or hospital budgets, the analysis suggests room for valuation improvement. However, an alternative community narrative identifies the stock as 13% overvalued due to rising legislative momentum around operating room air quality.
Form 4 CONMED Corporation: Hollie K. Foust (General Counsel & Corp Sec) For: 4 November
This article reports on a Form 4 filing for CONMED Corporation, indicating insider transaction activity by Hollie K. Foust, General Counsel & Corporate Secretary, related to November 4th. The filing provides transparency into executive stock transactions for the company (CNMD).
Conmed Corporation stock hits 52-week high at 53.7 USD By Investing.com
Conmed Corporation (CNMD) stock has reached a new 52-week high of $53.70, reflecting a 19.96% increase over the past year and over 31% in the last six months. InvestingPro analysis suggests the stock is undervalued with "GOOD" financial health. The company recently reported Q3 adjusted earnings that exceeded expectations but revenue slightly missed forecasts, and it has narrowed its growth outlook.
Conmed Corporation stock hits 52-week high at 53.7 USD
Conmed Corporation (CNMD) stock reached a 52-week high of $53.70, reflecting a 19.96% increase over the past year and over 31% in the last six months. Despite its strong performance, InvestingPro analysis suggests the stock is undervalued with "GOOD" financial health. The company recently reported Q3 adjusted earnings that exceeded expectations, although revenue slightly missed forecasts.
CONMED Corporation (CNMD) Seasonal Returns Chart - Yahoo Finance
This page provides historical seasonality data for CONMED Corporation (CNMD), showing average monthly price returns from 2016 to 2026. It indicates the stock's performance at market close and in after-hours trading on October 30. The primary content is a chart illustrating this seasonal data.
CONMED Corporation Stock 12‑Month Price Target Raised to $46.83, Implies 2% Upside
The average 12-month price target for CONMED Corporation stock has been raised from $45.5 to $46.83, based on estimates from six analysts, with a range of $43 to $50 per share. This updated target suggests a potential upside of approximately 2% from the Oct. 28 closing price. The consensus analyst rating for CONMED remains a "Hold" across seven analysts.
CONMED Corporation Q3 sales down 0.7% to USD 335.6M
CONMED Corporation announced its Q3 2026 financial results, reporting sales of $335.6 million, a 0.7% decrease year-over-year. Despite the overall decline, organic constant currency net sales increased by 6.7% when excluding strategic product line exits. The company's adjusted diluted EPS exceeded expectations, leading to an updated positive financial guidance for the full year 2026.
CONMED Corporation Stock 12‑Month Price Target Raised to $46, Implies 1% Upside
The average 12-month price target for CONMED Corporation stock has been raised from $45.5 to $46.83 by 6 analysts, implying a potential 2% upside from the October 28 closing price. Forecasts range from $43 to $50 per share, and the consensus rating among 7 analysts remains "Hold," with 0 Buys, 6 Holds, and 1 Sell recommendation.
Form 8K CONMED Corporation For: 28 October By Investing.com
This article from Investing.com announces the filing of a Form 8K by CONMED Corporation on October 28. A Form 8K is a crucial SEC filing used by public companies to announce major events that shareholders should know about. The article itself does not provide details of the filing but highlights the importance of such disclosures for investors.
CONMED 3Q 2026: Revenue $335.6M, Net income $19.8M, EPS $0.66— 10-Q Summary
CONMED (CNMD) reported its third-quarter 2026 financial results, with revenue at $335.6 million, a slight decrease from the prior year. Net income significantly increased to $19.8 million, leading to a diluted EPS of $0.66. The company saw growth in orthopedic sales, offsetting a decline in general surgery sales due to its exit from gastroenterology.
Press Release: CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED Corporation announced its financial results for the third quarter of 2026, reporting both GAAP and adjusted diluted net earnings per share, as well as revenue figures. The company also provided an update to its full-year 2026 financial guidance, adjusting its expectations for revenue and diluted net earnings per share. This release includes forward-looking statements regarding future performance.
CONMED Q3 2026 slides: organic growth strong amid portfolio shift
CONMED Corporation reported its Q3 2026 earnings, showcasing strong 6.7% organic constant currency growth despite a slight revenue miss and a 0.8% reported revenue decline due to strategic portfolio shifts. The medical device maker is exiting the gastroenterology market to focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. The company raised its full-year adjusted EPS guidance while narrowing its revenue outlook, reflecting confidence in profitability amid ongoing strategic transformation and challenges in the domestic orthopedic segment.
Conmed Q3 2026 Earnings Call Transcript
Conmed reported Q3 2026 net revenue of $335.6 million, exceeding expectations with adjusted diluted EPS of $1.04. The company achieved 6.7% organic constant currency revenue growth, driven by strong performance in general and orthopedic surgery, particularly from AirSeal, Buffalo Filter, and BioBrace. Conmed updated its full-year 2026 guidance, projecting 5% to 5.5% organic constant currency net sales growth and adjusted EPS between $4.54 and $4.61, while emphasizing strategic focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.
Earnings call transcript: CONMED tops Q3 2026 profit view, narrows growth outlook
CONMED Corp. (CNMD) reported adjusted Q3 2026 earnings per share of $1.04, beating Wall Street expectations, though revenue slightly missed forecasts at $335.6 million. The medical-device maker raised its full-year adjusted EPS guidance to $4.54-$4.61 but narrowed its organic constant-currency growth outlook to 5%-5.5%. Key growth drivers included AirSeal, Buffalo Filter, and BioBrace, with international growth offsetting some domestic challenges, particularly in U.S. orthopedics.
CONMED (NYSE:CNMD) Posts Earnings Results, Beats Estimates By $0.04 EPS
CONMED (NYSE:CNMD) announced its quarterly earnings, reporting $1.04 EPS, surpassing analyst estimates by $0.04, though revenue of $335.56 million was slightly below expectations. Following the announcement, shares fell $1.62 to $45.58 during Wednesday trading. The company's stock has a "Reduce" consensus rating and an average price target of $41.40 from analysts.
CONMED Reports Q3 2026 Net Income of $19.8 Million
CONMED Corporation reported third-quarter 2026 net sales of $335.6 million, a slight decrease of 0.7% year over year, but saw a significant rise in GAAP net income to $19.8 million compared to $2.9 million in the prior year. The company's GAAP diluted earnings per share were $0.66, and it updated its full-year 2026 net sales guidance to $1.360 billion to $1.366 billion, with adjusted diluted EPS guidance of $4.54 to $4.61. Hedge fund activity showed mixed interest in CONMED stock, with several institutions adding shares while others decreased their positions.
Form 10-Q CONMED Corp For: Sep 30
CONMED Corporation filed its Form 10-Q for the quarter ended September 30, 2026, detailing financial results, including a slight decrease in net sales but an increase in gross profit margins compared to the prior year. The company's net sales were impacted by its exit from gastroenterology product offerings, offset by growth in orthopedic surgery products. The report also highlights changes in operating expenses, interest expense, and the impact of debt refinancing activities.
Sales fell 0.7% at CONMED (CNMD), but quarterly net income rose.
CONMED Corporation (CNMD) reported a 0.7% year-over-year decrease in Q3 2026 net sales to $335.6 million, primarily due to exiting gastroenterology offerings. Despite this, quarterly net income significantly rose to $19.8 million from $2.9 million in the prior year, with gross margin expanding to 56.4%. For the first nine months of 2026, net sales also saw a slight decrease, but net income increased to $56.7 million from $30.3 million.
Form 8K CONMED Corporation For: 28 October By Investing.com
This article from Investing.com announces that CONMED Corporation filed a Form 8K on October 28. The brief report indicates the filing of this regulatory document, which often signifies significant events or changes within a company. The article includes the stock symbol CNMD and notes a -3.05% change.
Conmed (CNMD) Q3 Earnings Top Estimates
Conmed (CNMD) reported Q3 earnings of $1.04 per share, surpassing the Zacks Consensus Estimate of $1.00 per share, marking a 4% surprise. Despite beating earnings expectations, the company's Q3 revenues of $335.56 million missed the consensus estimate by 0.37%. Conmed's stock has performed well year-to-date, adding 16.3% compared to the S&P 500's 12.8% gain, and currently holds a Zacks Rank #3 (Hold).
CONMED Corporation (CNMD) Stock forecasts
Argus has lowered its target price for CONMED Corporation (CNMD) to $47.00. CONMED, a medical equipment company specializing in sports medicine and general surgeries, currently has a stock price of $44.42. The report was published on October 7, 2026.
Understanding Momentum Shifts in (CNMD)
This article provides an AI-driven analysis of Conmed Corp. (NASDAQ: CNMD), highlighting a weak near-term sentiment but an exceptional risk-reward setup targeting a 15.6% gain. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders. The report emphasizes the use of AI models to optimize position sizing and minimize drawdown risk.
CONMED Corporation (NYSE:CNMD) Stock Has Average Price Target of $41.40
CONMED Corporation (NYSE:CNMD) has received an average "Reduce" rating from eight research firms, with an average 1-year target price of $41.40, which is below its current share price of $45.20. Despite this cautious outlook, the company recently surpassed Q3 earnings expectations with $1.38 EPS against a $1.11 consensus and revenue of $343.49 million, exceeding the $337.60 million estimate. Institutional investors like BlackRock and Bank of America have also increased their positions in the medical technology company.
Conmed Corp (EC8.SG) Analyst insights, Price targets and Recommendations
This article provides analyst insights, price targets, and recommendations for Conmed Corp (EC8.SG). It lists recent upgrades and downgrades from various financial institutions, including Piper Sandler, Wells Fargo, BMO Capital, and B of A Securities. The current stock price for Conmed Corp (EC8.SG) is also displayed.
Conmed Corp (EC8.SG) Analyst Insights, Price Targets & Recommendations
This article provides an overview of recent analyst ratings and recommendations for Conmed Corp (EC8.SG). It lists several upgrades, downgrades, and maintained ratings from various financial institutions, along with their respective dates. The current stock price and change are also noted.
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
CONMED Corporation (NYSE: CNMD) announced it will report its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. Management will host a conference call at 4:30 p.m. ET on the same day to discuss the results, with webcast and telephone participation options available. This announcement is crucial for investors to assess the company's financial health and strategic execution within the medical technology sector.
Surgical equipment maker CONMED will hold a results call at 4:30 p.m. ET on Oct. 28.
CONMED Corporation announced it will report its third-quarter 2026 financial results after market close on October 28, 2026. The company's management will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can participate via live webcast or telephone.
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
CONMED Corporation (NYSE: CNMD) announced it will release its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can participate via live webcast or telephone, with replay available on their investor relations website.
CONMED Corporation (CNMD) Stock forecasts
This article provides stock forecasts for CONMED Corporation (CNMD). The content appears to be a stub or an error page from Yahoo Finance, displaying navigation and general financial market information rather than specific analysis or predictions for CNMD. It indicates that the UK markets are closed and shows various market indices and currency rates.
CONMED Corporation (CNMD) Stock forecasts
Argus has lowered its target price for CONMED Corporation (CNMD) to $48.00, citing the medical equipment company's focus on sports medicine and general surgeries. The current stock price for CNMD is $45.18. The report, published on September 23, 2026, provides a summary of the company's business activities.
Bank of America Corp DE Acquires Shares of 1,341,409 CONMED Corporation $CNMD
Bank of America Corp DE has acquired a new stake of 1,341,409 shares in CONMED Corporation, valued at approximately $43.9 million, giving it a 4.48% ownership. Despite this significant investment, analyst sentiment remains cautious with a consensus "Reduce" rating and a price target of $41.40 for CONMED. The medical technology company recently exceeded quarterly expectations with EPS of $1.38 and revenue of $343.5 million, though its stock opened down 1.3% at $44.84.
Conmed Corp (EC8.MU) Analyst Insights, Price Targets & Recommendations
This article provides an overview of analyst insights for Conmed Corp (EC8.MU), including recent reiterations, initiations, and downgrades from various financial institutions. The stock is currently trading at 40.00 EUR, down 0.50% as of the last update. It lists several analyst actions from July, June, and May 2026, indicating a mixed sentiment ranging from Neutral to Underperform.
(CNMD) Movement as an Input in Quant Signal Sets
This article provides an in-depth quantitative analysis of Conmed Corp. (NASDAQ: CNMD), highlighting a neutral near-term sentiment with potential for moderate mid-term weakness. It identifies an exceptional short setup with a 48.6:1 risk-reward ratio, targeting a 14.2% downside. The analysis offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
CONMED Corporation (NYSE:CNMD) Receives Average Recommendation of "Reduce" from Brokerages
CONMED Corporation (NYSE:CNMD) has received an average "Reduce" rating from eight analysts, with two recommending "sell" and six "hold." Despite exceeding quarterly earnings expectations with an EPS of $1.38 and revenue of $343.49 million, the average 12-month price target is $41.40, below its current share price of $46.15. Institutional investors like BlackRock and Bank of America have recently increased their positions in the company, while the California State Teachers’ Retirement System significantly boosted its stake.
CONMED (CNMD) Stock Price, News & Analysis
CONMED Corporation (NYSE:CNMD) is a medical technology company specializing in surgical devices and equipment. The stock currently has a "Reduce" consensus rating from analysts, with a target price suggesting a potential downside. Key stats indicate a market capitalization of $1.40 billion and a P/E ratio of 25.26, while the company does not pay a dividend.
CONMED Director Kim Kelderman Awarded 500 RSUs Under 2025 Long-Term Incentive Plan
CONMED Corp (NASDAQ:CNMD) director Kim Kelderman was granted 500 restricted stock units (RSUs) on September 8, 2026, as part of the company's 2025 Long-Term Incentive Plan. The RSUs, acquired at a $0 price, vest 100% after one year, bringing Kelderman's direct ownership to 500 common shares. This transaction was reported in a Form 4 filing on September 10, 2026.
CONMED at Wells Fargo conference: growth story gains momentum
CONMED Corporation (CNMD) presented at the Wells Fargo 21st Annual Healthcare Conference, highlighting its accelerating growth driven by minimally invasive surgery, international expansion, and margin improvements. The company expects second-half 2026 revenue growth to accelerate to 6-8%, supported by key products like AirSeal, BioBrace, and Buffalo Filter, while also prioritizing de-leveraging and strategic tuck-in acquisitions. Management emphasized CONMED's transition from a stable mid-single-digit grower to a faster-moving company with enhanced operating leverage and strong free cash flow generation.
CONMED (CNMD) director receives 500 shares as stock units vest
CONMED director Kim Kelderman converted 500 restricted stock units (RSUs) into 500 common shares on September 8, 2026. This transaction was part of his equity compensation under CONMED's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after one year. Following the conversion, Kelderman directly holds 500 common shares and 0 RSUs.
291,203 Shares in CONMED Corporation $CNMD Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp has acquired 291,203 shares of CONMED Corporation (NYSE:CNMD), valued at approximately $9.5 million, representing about 0.97% of the company. Other institutional investors like AQR Capital Management and Intech Investment Management also increased their stakes, while Creative Planning initiated a new position. Despite CONMED beating quarterly earnings estimates with $1.38 EPS and $343.5 million in revenue, analysts maintain a "Reduce" rating with a consensus price target of $41.40.
BlackRock Inc. Invests $157.78 Million in CONMED Corporation $CNMD
BlackRock Inc. has invested approximately $157.78 million in CONMED Corporation, acquiring 4.82 million shares and taking a 16.1% stake in the medical technology company. This investment comes as CONMED exceeded its quarterly earnings expectations, reporting adjusted EPS of $1.38 and revenue of $343.5 million, and provides a fiscal 2026 EPS guidance of $4.48–$4.60. Despite this significant institutional interest, analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $41.40.
Technical Reactions to CNMD Trends in Macro Strategies
This article provides a technical analysis of Conmed Corp. (NASDAQ: CNMD), highlighting weak near-term sentiment that may lead to a resumption of long-term weakness. It presents institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. The company reported strong Q2 2026 earnings and revenues, beating estimates, with organic sales gaining momentum, particularly in international markets and Orthopedic Surgery. Despite some declines in General Surgery due to GI portfolio exits, the company has updated its 2026 guidance with a higher projected EPS.
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
CONMED Corporation (NYSE: CNMD) announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026. Management will host a fireside chat on September 9th at 1:30 p.m. Eastern Time, which will be accessible via a live audio webcast and a subsequent replay on the company's investor relations website.
CONMED offers a live webcast and about 90 days of replay access
CONMED Corporation (NYSE: CNMD) announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026, in Everett, MA. Management will participate in a fireside chat on September 9th at 1:30 p.m. Eastern Time. A live audio webcast will be available on the company's investor relations website, with a replay accessible for approximately 90 days.
3 Reasons to Avoid CNMD and 1 Stock to Buy Instead
This article advises investors to avoid CONMED (CNMD) despite its recent market performance, citing three main reasons: weak constant currency growth, limited distribution channels due to its small size, and slim projected revenue growth. The author suggests that while CNMD's valuation is reasonable, its shaky fundamentals present too much downside risk and recommends considering other, more entrenched companies.
CONMED (NYSE:CNMD) Draws Focus After Strong Results
CONMED Corporation (NYSE:CNMD) is drawing market attention due to its strong quarterly financial performance, operational improvements, and sustained demand for its surgical technology solutions. The company's focus on advanced medical technologies and its diversified product portfolio, catering to various medical specialties, have contributed to its growth. Despite mixed market sentiment regarding valuation, CONMED's innovation and financial discipline are strengthening its position in the healthcare industry.